Market research
OCUL Ocular Therapeutix Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 2B
- P/E ratio
- Not available
- Analyst target
- 27.0909
- Dividend yield
- Not available
- Beta
- 0.94
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US67576A1007
- Market cap
- 2B
- P/E ratio
- Not available
- Analyst target
- 27.0909
- Dividend yield
- Not available
- Beta
- 0.94
About
About Ocular Therapeutix Inc
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the OCUL discussion.
5 years, 4 months ago
Ocular Therapeutix, Inc is currently in a long term downtrend where the price is trading 19.6% below its 200 day moving average.
From a valuation standpoint, the stock is 95.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 60.2.
Ocular Therapeutix, Inc's total revenue rose by 225.8% to $7M since the same quarter in the previous year.
Its net income has dropped by 229.1% to $-86M since the same quarter in the previous year.
Finally, its free cash flow grew by 67.6% to $-6M since the same quarter in the previous year.
Based on the above factors, Ocular Therapeutix, Inc gets an overall score of 3/5.